Publications by Dr Elaine Willmore - ePrints

Browsing publications by Dr Elaine Willmore.

Newcastle Authors	Title	Year
Hannah Smith Dr Elaine Willmore Dr Lisa Prendergast Professor Nicola Curtin	ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors	2024
Dr Celine Cano Professor Jane Endicott Dr Ian Hardcastle Dr Claire Jennings Suzanne Kyle et al.	Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile	2024
Erhan Aptullahoglu Dr Jonathan Wallis Dr Helen Marr Dr Elaine Willmore Professor John Lunec et al.	SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia	2023
Dr Jill Hunter Dr Elaine Willmore Professor Julie Irving Dr Stephany Veuger	Correction to: NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699 (Oncogene, (2012), 31, 2, (251-264), 10.1038/onc.2011.229)	2023
Dr Evan Mulligan Dr Susan Tudhope Dr Jill Hunter Sarah Elliott Dr Jonathan Wallis et al.	Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling	2023
Dr Beth Adamson Nicholas Brittain Dr Laura Walker Ruaridh Duncan Dr Sara Luzzi et al.	The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer	2023
Hannah Smith Dr Elaine Willmore Dr Asima Mukhopadhyay Dr Yvette Drew Professor Nicola Curtin et al.	Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling	2022
Dr Carmela Ciardullo Dr Katarzyna Szoltysek Dr Peixun Zhou Dr Elaine Willmore Dr Amir Enshaei et al.	Low BACH2 expression predicts adverse outcome in chronic lymphocytic leukaemia	2022
Islam Al-Khawaldeh Dr Christine Basmadjian Dr Cinzia Bordoni Dr Suzannah Harnor Amy Heptinstall et al.	An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)	2021
Dr Timothy Barrow Dr Elaine Willmore Dr Gordon Strathdee Dr Hyang-Min Byun	Analysis of retrotransposon subfamily DNA methylation reveals novel early epigenetic changes in chronic lymphocytic leukaemia	2021
Dr Timothy Barrow Dr Sirintra Nakjang Kateryna Bilotkach Dr Laura Woodhouse Gesa Junge et al.	Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia	2021
Dr Wei-Yu Lin Dr Sarah Fordham Dr Nicola Sunter Dr Claire Elstob Dr Thahira Rahman et al.	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia	2021
Dr Elaine Willmore	Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL	2021
Dr Katarzyna Szoltysek Dr Carmela Ciardullo Dr Peixun Zhou Dr Anna Walaszczyk Dr Elaine Willmore et al.	Dap kinase-related apoptosis-inducing protein kinase 2 (Drak2) is a key regulator and molecular marker in chronic lymphocytic leukemia	2020
Dr Carmela Ciardullo Erhan Aptullahoglu Dr Laura Woodhouse Dr Wei-Yu Lin Dr Jonathan Wallis et al.	Non-genotoxic MDM2 inhibition selectively induces pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells	2019
Dr Catherine Willoughby Huw Thomas Dr Elaine Willmore Suzanne Kyle Dr Anita Wittner et al.	Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy	2019
Dr Celine Cano Dr Suzannah Harnor Dr Elaine Willmore Professor Steve Wedge	Targeting DNA-PK as a Therapeutic Approach in Oncology	2018
Dr Carmela Ciardullo Dr Elaine Willmore Dr Amir Enshaei Dr Peixun Zhou Dr Vikki Rand et al.	BACH2 and BCL6 Cooperatively Fuction as Tumour Suppressors in CLL	2016
Dr Carmela Ciardullo Dr Elaine Willmore Dr Peixun Zhou Dr Vikki Rand Professor Christine Harrison FRCPath FMedSci et al.	Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia	2016
Dr Carmela Ciardullo Dr Peixun Zhou Dr Elaine Willmore Professor Christine Harrison FRCPath FMedSci Dr Andrew Hall et al.	Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia	2016
Dr Timothy Barrow Dr Laura Woodhouse Gesa Junge Dr Susan Tudhope Dr Jonathan Wallis et al.	The Role of HOXA4 in Chronic Lymphocytic Leukaemia Progression and Response to Therapy	2016
Dr Laura Woodhouse Clark Crawford Dr Scott Marshall Dr Nicholas Bown Dr Elaine Willmore et al.	Assessment and targeting of the MDM2-p53 network in CLL	2015
Dr Elaine Willmore Dr Aaron Ions Gardner Dr Susan Tudhope Belinda Murtani Jessica Caffry et al.	Novel small molecule IKK alpha inhibitors inhibit non- canonical NF-kappa B signaling and survival of primary CLL cells	2015
Dr Ashleigh Herriott Dr Susan Tudhope Gesa Junge Natalie Rodrigues Dr Miranda Patterson et al.	PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia	2015
Laura Evans Dr Lindi Chen Dr Elaine Willmore Professor Herbie Newell Professor Deborah Tweddle et al.	SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma	2015
Andrew Shouksmith Laura Evans Professor Deborah Tweddle Duncan Miller Dr Elaine Willmore et al.	Synthesis and Activity of Putative Small-Molecule Inhibitors of the F-Box Protein SKP2	2015
Emily Mould Professor Herbie Newell Dr Elaine Willmore	DNA-PK is activated by microtubule-targeting agents; mechanistic studies using isogenic wild-type and DNA-PK knockout cells	2014
Emily Mould Philip Berry Dr David Jamieson Dr Chris Hill Dr Celine Cano et al.	Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity	2014
Pawel Znojek Dr Elaine Willmore Professor Nicola Curtin	Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase	2014
Dr Alessio Iannetti Dr Adeline Ledoux Dr Susan Tudhope Helene Sellier Adam Moore et al.	Regulation of p53 and Rb Links the Alternative NF-kappaB Pathway to EZH2 Expression and Cell Senescence	2014
Emily Mould Stephanie Burnell Philip Berry Professor Herbie Newell Dr Elaine Willmore et al.	The novel and contrasting roles of ATM and DNA-PK in the response of cells to microtubule-targeting anticancer agents	2014
Emily Mould Philip Berry Dr David Jamieson Dr Chris Hill Niu Tan et al.	The DNA-PK inhibitor, NU7441, sensitises cancer cells to microtubule-targeting agents and modulates vincristine efflux in multidrug resistant cells	2013
Shilu Amin Dr Meagan Walsh Dr Caroline Wilson Dr Elaine Willmore Professor Derek Mann et al.	Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL	2012
Dr Elaine Willmore Natalie Rodrigues Dr Jonathan Wallis Professor Nicola Curtin	High Activity of Poly(ADP-Ribose) Polymerase in Chronic Lymphocytic Leukemia	2012
Dr Jill Hunter Dr Elaine Willmore Professor Julie Irving Dr Stephany Veuger Professor barbara Durkacz et al.	NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699	2012
Dr Susan Tudhope Dr Evan Mulligan Dr Jill Hunter Dr Helen Marr Professor barbara Durkacz et al.	P B S-1086, a "Pan-Rel" Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells	2012
Dr sarah Johnson Clark Crawford Dr Evan Mulligan Dr Jonathan Wallis Dr Tryfonia Mainou-Fowler et al.	Mitoxantrone in combination with an inhibitor of DNA-dependent kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia	2011
Dr Elaine Willmore Dr Evan Mulligan Dr Sarah Elliott Professor barbara Durkacz	ATM Mutant Chronic Lymphocytic Leukaemia Cells are Chemosensitized by Inhibition of DNA Dependent Protein Kinase	2010
Dr sarah Johnson Dr Tryfonia Mainou-Fowler Professor barbara Durkacz Dr Elaine Willmore	Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: A potential therapy for poor risk B-cell chronic lymphocytic leukaemia	2010
Dr Evan Mulligan Arabella Baird Dr Jonathan Wallis Dr Stephany Veuger Professor barbara Durkacz et al.	Relationships Between Aberrant Activity of the NF-kappa B Subunits and Outcome In Chronic Lymphocytic Leukemia: The Dual Role of DNA Damage Sensor Enzymes	2010
Dr Nicola Sunter Dr Ian Cowell Dr Elaine Willmore Gary Watters Professor Caroline Austin et al.	Role of Topoisomerase IIbeta in DNA Damage Response following IR and Etoposide	2010
Dr Miguel Lopez-Lazaro Dr Elaine Willmore Professor Caroline Austin	The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells	2010
Dr Elaine Willmore Dr sarah Johnson Dr Tryfonia Mainou-Fowler Professor Graham Jackson Dr Celine Cano et al.	DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia	2008
Dr Elaine Willmore Dr sarah Johnson Clark Crawford Dr Tryfonia Mainou-Fowler Professor Graham Jackson et al.	DNA-Dependent Protein Kinase Is a Therapeutic Target in Poor Prognosis B-Cell Chronic Lymphocytic Leukemia	2008
Andrew Jobson Dr Elaine Willmore Dr Michael Tilby Professor Caroline Austin	Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases	2008
Dr Miguel Lopez-Lazaro Dr Elaine Willmore Dr sarah Johnson Professor Caroline Austin	Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells	2008
Dr Miguel Lopez-Lazaro Dr Elaine Willmore Professor Caroline Austin	Cells lacking DNA topoisomerase IIβ are resistant to genistein	2007
Dr Miguel Lopez-Lazaro Dr Elaine Willmore Andrew Jobson Kathryn Gilroy Hannah Curtis et al.	Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells	2007
Dr Elaine Willmore Professor Graham Jackson Dr Tryfonia Mainou-Fowler Professor Caroline Austin Professor barbara Durkacz et al.	Sensitisation of B-CLL cells to chlorambucil and fludarabine via inhibition of the DNA damage sensor proteins, DNA-PK and ATM	2006
Dr Elaine Willmore Dr Tryfonia Mainou-Fowler Professor Graham Jackson Professor barbara Durkacz	Targeting DNA-PK and ATM increases sensitivity to chlorambucil and fludarabine in chemoresistant and p53-defective B-CLL cells	2006
Lisa Smith Dr Elaine Willmore Professor Caroline Austin Professor Nicola Curtin	The novel poly(ADP-ribose) polymerase inhibitor, AG14361 sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks	2005
Dr Elaine Willmore Dr Nicola Sunter Dr Michael Tilby Professor Graham Jackson Professor Caroline Austin et al.	A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia	2004
Fiona Errington Dr Elaine Willmore Chrysoula Leontiou Dr Michael Tilby Professor Caroline Austin et al.	Differences in the longevity of topo IIα and topo IIβ drug-stabilized cleavable complexes and the relationship to drug sensitivity	2004
Dr Elaine Willmore Professor Caroline Austin	Alchemix: A novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer	2003
Dr Elaine Willmore Professor Jeremy Lakey Professor Caroline Austin	Characterisation of the DNA-dependent ATPase activity of human DNA topoisomerase IIß: mutation of Ser165 in the ATPase domain reduces the ATPase activity and abolishes the in vivo complementation ability	2002
Andrew Jobson Dr Elaine Willmore Dr Michael Tilby Professor Caroline Austin	Characterisation of the roles of Topoisomerase I and II in the mechanism of action of novel anti-tumour agents XR11576 (MLN576) and XR5944 (MLN944)	2002
Dr Elaine Willmore Fiona Errington Dr Michael Tilby Professor Caroline Austin	Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells	2002
Dr Elaine Willmore Dr Michael Tilby Professor Caroline Austin Professor barbara Durkacz	Potentiation of topoisomerase II poison cytotoxicity in the K562 human leukaemia cell line by the novel DNA-dependent protein kinase inhibitor NU7026	2002
Dr Elaine Willmore Professor Caroline Austin Professor Nicola Curtin	The role of poly(ADP-ribose) polymerase-1 (PARP-1) in the cellular response to topoisomerase I poisons	2002
Fiona Errington Dr Elaine Willmore Dr Michael Tilby Professor Caroline Austin	Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation	1999
Dr Elaine Willmore Dr Adrian Frank Dr Kay Padget Dr Michael Tilby Professor Caroline Austin et al.	Etoposide targets topoisomerase IIα and IIβ in leukemic cells: Isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique	1998
Dr Ian Cowell Dr Elaine Willmore Dr David Allen Chalton Professor Caroline Austin	Nuclear distribution of human DNA topoisomerase IIβ: A nuclear targeting signal resides in the 116-residue C-terminal tail	1998
Dr Elaine Willmore Dr Emma Meczes Professor Caroline Austin	Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms α and β	1996
Dr Elaine Willmore Professor Caroline Austin	Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180)	1996
Professor Caroline Austin Dr Elaine Willmore	Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity	1996
Professor Caroline Austin Dr Elaine Willmore	Expression, domain structure and enzymatic properties of an active recombinant human DNA topoisomerase II beta	1995
Dr Elaine Willmore Professor barbara Durkacz	The effects of 5-fluoropyrimidines on nascent DNA synthesis in Chinese hamster ovary cells monitored by pH-step alkaline and neutral elution.	1994
Dr Elaine Willmore Professor barbara Durkacz	Cytotoxic mechanisms of 5-fluoropyrimidines: Relationships with poly(ADP-ribose) polymerase activity, DNA strand breakage and incorporation into nucleic acids	1993
Dr Elaine Willmore Professor barbara Durkacz	Correlation of enhanced 6-mercaptopurine cytotoxicity with increased phosphoribosylpyrophosphate levels in Chinese hamster ovary cells treated with 3-aminobenzamide	1990